Refine by
Genomic Editing Articles & Analysis
26 news found
The emerging Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system has greatly improved the efficiency of genome editing and simplified multilocus genome editing steps. It has also enabled the rapid disruption of metabolic networks. ...
For example, utilizing CRISPR/Cas9 and other genome-editing tools, scientists are exploring ways to correct mutations that lead to glaucoma. ...
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. ...
They enable the true on/off-target mutations of genome editing experimentation to be determined in conjunction with genome-wide off-target detection systems (GUIDE-seq, WGS) at high sensitivity and in a non-biased way. ...
Agreement strengthens Bayer’s new cell and gene therapy platform further Supports Mammoth’s vision of unlocking the full potential of novel CRISPR systems Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more than one billion USD upon successful achievement Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity ...
, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. ...
This year, it attracts a great number of researchers who are interested in accelerating oligonucleotide, peptide, mRNA, and genome editing products from early discovery to late-stage development and commercialization. ...
Namely, deletion of fucosyltransferase and xylosyltranferase genes was achieved through precision genome editing. The resulting lysate devoid of plant glycans, opens the door to a new line of ALiCE products offering the potential for customizable protein glycosylation. ...
This strategy is enabled by our proprietary Cas12a chRDNA genome-editing technology that reproducibly achieves high specificity genome editing at multiple ...
Recent appointments to the Mammoth leadership team also include Adriana Dantas Lemberg, Vice President, Product Management, and Dimitrios Zisoulis, Vice President, Genome Engineering. Ms. Dantas Lemberg has more than two decades of experience in the medical device IVD space, leading product development, marketing and sales organizations at Roche and Becton Dickinson. ...
By leveraging its internal research and development and exclusive licensing to patents related to Cas12, Cas13, Cas14 and CasΦ, Mammoth Biosciences can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. ...
, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. ...
For research applications requiring highly precise genome editing, including engineering CAR T cells and creating cellular models for disease discovery, the Invitrogen TrueCut HiFi Cas9 Protein* significantly minimizes off-target events while retaining maximum on-target editing efficiency. Thermo Fisher Scientific introduced the new protein to ...
“We believe our novel ultra-small CRISPR systems have the potential to be game changers when it comes to systemic and targeted delivery of in vivo gene-editing therapies,” said Peter Nell, Chief Business Officer and Head of Therapeutic Strategy at Mammoth Biosciences. ...
The funds will enable the company to broaden its toolkit of next-generation CRISPR systems with a focus on building permanent genetic cures through in vivo gene-editing therapeutics and democratizing disease detection with on-demand diagnostics. ...
The company’s cell+gene platform enables the creation, manufacture, and delivery of authentic cell therapies with engineered functionality by simultaneously harnessing pluripotent cell biology and genome editing. This enables an approach where, in theory, any cell in the body can be manufactured and any gene in the genome can be engineered ...
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer?AG, announced?today?that Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021. Current Chief Scientific Officer Seth Ettenberg, Ph.D., will assume the role of President and CEO. BlueRock will continue in its mission ...
The company’s cell+gene platform enables the creation, manufacture, and delivery of authentic cell therapies with engineered functionality by simultaneously harnessing pluripotent cell biology and genome editing. This enables an approach where, in theory, any cell in the body can be manufactured and any gene in the genome can be engineered ...
The company’s cell+gene platform enables the creation, manufacture, and delivery of authentic cell therapies with engineered functionality by simultaneously harnessing pluripotent cell biology and genome editing. This enables an approach where, in theory, any cell in the body can be manufactured and any gene in the genome can be engineered ...
The company’s cell+gene platform enables the creation, manufacture, and delivery of authentic cell therapies with engineered functionality by simultaneously harnessing pluripotent cell biology and genome editing. This enables an approach where, in theory, any cell in the body can be manufactured and any gene in the genome can be engineered ...